Wang, LuhuaLuhuaWangWu, Yi LongYi LongWuLu, ShunShunLuDeng, LeiLeiDengAhn, Myung JuMyung JuAhnFENG-MING HSUIscoe, NeillNeillIscoeHossain, AnwarAnwarHossainPuri, TarunTarunPuriZhang, PinghaiPinghaiZhangOrlando, MauroMauroOrlando2020-05-022020-05-022016-12-0117437555https://scholars.lib.ntu.edu.tw/handle/123456789/487466© 2016 John Wiley & Sons Australia, Ltd Aim: PROCLAIM, a phase III trial of patients with nonsquamous non–small cell lung cancer comparing concurrent pemetrexed-cisplatin and thoracic radiation therapy followed by consolidation pemetrexed, did not meet its primary endpoint of superior overall survival versus etoposide-cisplatin and thoracic radiation therapy followed by a consolidation platinum doublet of choice. The results from an East Asian subgroup analysis are presented here. Methods: A subgroup analysis was performed for all patients randomized from China (n = 61), Taiwan (n = 25), and Korea (n = 11). Results: Baseline characteristics were balanced between treatment arms for East Asian patients. In the 97 randomized East Asian patients, median overall survival was 26.8 months for the pemetrexed-cisplatin arm and 36.3 months for the etoposide-cisplatin arm (hazard ratio: 1.23; 95% confidence interval: 0.70–2.14; P = 0.469). Median progression-free survival was 10.0 months for the pemetrexed-cisplatin arm and 7.6 months for the etoposide-cisplatin arm (hazard ratio: 0.97; 95% confidence interval: 0.61–1.54; P = 0.890). The objective response rate was 47.7% in the pemetrexed-cisplatin arm and 34.0% in the etoposide-cisplatin arm (P = 0.167). In the 90 treated East Asian patients, the overall incidence of drug-related grade 3–4 treatment-emergent adverse events was significantly lower in the pemetrexed-cisplatin arm versus the etoposide-cisplatin arm (61.4% vs 91.3%; P = 0.001). Conclusion: For East Asian patients, pemetrexed-cisplatin combined with thoracic radiation therapy, followed by consolidation pemetrexed, did not improve overall survival but did have a good safety profile with a trend for improved progression-free survival and objective response rate compared to standard chemoradiotherapy for stage III unresectable nonsquamous non–small cell lung cancer.Asians | carcinoma | chemoradiotherapy | combined modality therapy | non–small cell lungAsians; carcinoma; chemoradiotherapy; combined modality therapy; non–small cell lung[SDGs]SDG3carboplatin; cisplatin; etoposide; navelbine; paclitaxel; pemetrexed; antineoplastic agent; cisplatin; etoposide; pemetrexed; adult; advanced cancer; aged; anorexia; Article; cancer radiotherapy; China; consolidation chemotherapy; constipation; controlled study; drug efficacy; drug safety; dysphagia; East Asian; esophagitis; fatigue; female; human; inoperable cancer; Korea; lung infiltrate; lymphocytopenia; major clinical study; male; multicenter study; multiple cycle treatment; nausea; non small cell lung cancer; overall survival; phase 3 clinical trial; pneumonia; priority journal; progression free survival; side effect; Taiwan; thorax; treatment response; vomiting; Carcinoma, Non-Small-Cell Lung; clinical trial; consolidation chemotherapy; middle aged; pathology; procedures; randomized controlled trial; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Consolidation Chemotherapy; Etoposide; Female; Humans; Male; Middle Aged; Pemetrexedjournal article10.1111/ajco.12513273125142-s2.0-84976563864WOS:000393076500009https://api.elsevier.com/content/abstract/scopus_id/84976563864